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Summary Sudden unexplained/unexpected death (SUDEP) in epilepsy is a major
cause of death accounting for 7—17% of the mortality among epileptic patients.
Prolongation of QT-interval has been issued as a major mechanism in SUDEP since it is
associated with fatal cardiac arrhythmias. This condition may be further precipitated
by anti-epileptic treatment.
Despite thorough literature research, we did not find any reports suggesting that
primidone is responsible for QT-prolongation. On the contrary, all the retrieved
reports addressed that the drug shortened QT-interval and corrected signs and
symptoms of the underlying disease.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Sudden unexplained/unexpected death (SUDEP) in
epilepsy is a major cause of death accounting for
7—17% of the mortality among general epileptic
population and for up 50% among patients
with refractory epilepsy.1 The molecular basis of
SUDEP remains unclear although many potential
patho-mechanisms have been suggested. Cardiac
arrhythmias, electrolyte disturbances, administra-* Corresponding author. Tel.: +30 2651 036203.
E-mail address: pacmer_science@yahoo.com (D. Christidis).
1059-1311/$ — see front matter # 2006 British Epilepsy Association
doi:10.1016/j.seizure.2005.10.002tion of arrhythmogenie drugs and central or
obstructive apnea are to date proposed as possible
causes.
Prolongation of QT-interval has been issued as a
major mechanism of cardiac arrhythmias-related
SUDEP, and it may be precipitated by anti-epileptic
treatment.2
In a recent review article Stollberger and
Finsterer2 analyzed the strict relationship between
anticonvulsant therapy and QT-prolongation. Sur-
prisingly primidone was considered to be an agent
with potential arrhythmogenic effect attributed to
QT-lengthening.2 This is in fact in straight contrast. Published by Elsevier Ltd. All rights reserved.
Primidone the drug of choice for epileptic patients 65with the current knowledge, which considers primi-
done as the only anticonvulsant drug able to shorten
QT-interval and correct cardiac arrhythmias.3
Consequently, considering the importance of pri-
midone therapy in epileptic patients with syncope
and prolonged QT-interval, and the possible conse-
quences of removing the only anti-epileptic com-
pounds with the over mentioned characteristics, we
performed a comprehensive review of literature.Materials and methods
In order to retrieve studies analyzing the impact of
primidone therapy on QTwe performed a systematic
search of medical literature in four libraries
(Cochrane, PubMed, EMBASE and ISI Science Citation
Index) with the following searching algorithms:
QT AND (primidone OR mysoline)
(QT length OR sudden death OR SUDEP) AND
(primidone OR mysoline)
We set no year and no language restriction. In
order to implement the literature-search feasibility,
the reference list of retrieved papers was further
screened for possible reports. Potentially eligible
papers were selected by abstract or title. In case ofTable 1 Case reports analyzing primidone’s effect on QT-i
Author Year of
publication
Gender/
Age
Underlying cond
DeSilvey
and Moss
1980 F/31 Grand mal seizu
Prolonged QT-int
Episodes of vent
tachycardia
F/16 Seizure
Prolonged QT-int
M/15 Seizure
Prolonged QT-int
Lan 1986 F/20 Recurrent synco
Seizure
Prolonged QT-int
F/19 Recurrent synco
Seizure
Neurogenie deaf
Prolonged QT-int
M/23 Recurrent synco
Seizure
Prolonged QT-int
M/13 Recurrent synco
Seizure
Prolonged QT-int
Loukeris
et al.
2002 M/17 Epilepsy (West sdoubts during the data processing from full-text
reports, we personally contacted the first author
for clarifications.Results
Despite an extensive literature search we were able
to retrieve only three eligible studies.3—5 All of the
studies were case reports, two manuscripts were in
English and one in Chinese language. A total number
of eight patients were available for analysis.
In all eight patients the administrations of primi-
done was followed by QT-shortening and symptoms
remission (seizure, syncope, torsade des pointes,
arrhytmia). The clinico-pathologic features of each
patient are reported in Table 1.Discussion
Clinicians are often faced with cardiac arrhythmias
accompanying epilepsy or complicating anti-epi-
leptic therapy. QT-lengthening with torsades de
pointes is a potentially fatal form of ventricular
arrhythmia with increased incidence among
patients suffering from epilepsy. This type ofnterval
ition(s) Drug action Follow up
(months)
re Seizure control 24
erval QT-shortening
ricular Arrhythmia suppression
Seizure control 8
erval QT-shortening
Seizure control NR
erval QT-shortening
pe QT-shortening 36
Arrhythmia suppression
erval Syncope and seizure control
pe QT-shortening 36
Arrhythmia suppression
ness Syncope control
erval
pe QT-shortening 36
Arrhythmia suppression
erval Syncope control
pe QT-shortening 36
Arrhythmia suppression
erval Syncope control
yndrome) QT-shortening 12
66 D. Christidis et al.arrhythmia is precipitated by the administration of
certain anticonvulsant agents.
Primidone’s favorable influence on QT-interval
may offer an alternative in management of epilepsy
and essential tremor when special arrhythmogenic
considerations (as QT-prolongation with or without
torsades de pointes) are taken into account. Despite
literature is poor, we did not find any reports incul-
pating primidone for QT-lengthening, on the oppo-
site, all the retrieved reports address that the drug
shortened QT and corrected signs and symptoms of
the underlying disease.
We thus disagree with the recent review of
Stollberger and Finsterer2 by the statement that
primidone may be responsible for QT-prolonga-
tion. According to authors, the aforementioned
conclusion stems from a case reported by Loukeris
et al.4
Loukeris et al. reported a case of severe hypo-
calcemia associated with chronic anticonvulsant
therapy with sodium valproate and primidone. In
that case, QT-prolongation was disproportionate for
the degree of hypocalcemia and serum calciumcorrection accompanied by only a slight shortening
QT-interval.
There is therefore the suggestion that primidone
effect may be beneficial in QT-interval shortening;
anyhow since only eight cases had been described in
literature a firm conclusion may not be drawn. Due
to the paucity of reports the mechanism of actions is
not fully understood.References
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